Evidence map›Paper›PMID 27704016›Full record

ArticleOpen forum infectious diseases2016

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile.

Andrew N Phillips, Valentina Cambiano, Fumiyo Nakagawa, Deborah Ford, Tsitsi Apollo, Joseph Murungu, Christine Rousseau, Geoff Garnett, Peter Ehrenkranz, Loveleen Bansi-Matharu and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Using HIV antibody measurements to detect viral load rebound: An analysis from an analytic treatment interruption study in the United States.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Observational
  4. The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Andrew N PhillipsDepartment of Infection and Population Health , University College London (UCL) , United Kingdom.
Valentina CambianoDepartment of Infection and Population Health , University College London (UCL) , United Kingdom.
Fumiyo NakagawaDepartment of Infection and Population Health , University College London (UCL) , United Kingdom.
Deborah FordMRC Clinical Trials Unit at UCL , Institute of Clinical Trials and Methodology , London , United Kingdom.
Tsitsi ApolloMinistry of Health and Child Care , Causeway, Harare , Zimbabwe.
Joseph MurunguMinistry of Health and Child Care , Causeway, Harare , Zimbabwe.
Christine RousseauBill & Melinda Gates Foundation , Seattle, Washington.
Geoff GarnettBill & Melinda Gates Foundation , Seattle, Washington.
Peter EhrenkranzBill & Melinda Gates Foundation , Seattle, Washington.
Loveleen Bansi-MatharuDepartment of Infection and Population Health , University College London (UCL) , United Kingdom.
Lara VojnovClinton Health Access Initiative , Boston, Massachusetts.
Zachary KatzClinton Health Access Initiative , Boston, Massachusetts.
Rosanna PeelingClinical Research Department , London School of Hygiene and Tropical Medicine , United Kingdom.
Paul RevillCentre for Health Economics , University of York , Heslington , United Kingdom.

Funding

Medical Research Council MC_UU_12023/23
6 · The paper itself

Abstract

Point-of-care viral load tests are being developed to monitor patients on antiretroviral therapy (ART) in sub-Saharan Africa. Test design involves trade-offs between test attributes, including accuracy, complexity, robustness, and cost. We used a model of the human immunodeficiency virus epidemic and ART program in Zimbabwe and found that the attributes of a viral load testing approach that are most influential for cost effectiveness are avoidance of a high proportion of failed tests or results not received, use of an approach that best facilitates retention on ART, and the ability to facilitate greater use of differentiated care, including through expanding coverage of testing availability.

Indexed as

antiretroviral therapycost-effectivenessmodelpoint-of-careviral load

Identifiers

PMID27704016
PMCPMC5047406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.